Angiotensin Converting Enzymes (ACE) Inhibitors Are Proving To Be Critical For Treatment of Low Blood Pressure

 

Angiotensin Converting Enzymes (ACE), a protein compound synthesized from angiotensin, have multiple applications in the field of medication and therapy. Angiotensin converting enzymes (ACE) inhibitors are frequently prescribed for the management of various cardiovascular conditions including heart failure, artery disease, and hypertension. The efficacy of ACE inhibitors in the management of high blood pressure is supported by extensive data obtained from rigorous clinical trials and experimental studies. Moreover, they have been shown to reduce the risk of stroke in human beings and they also have an important role in the control of type 2 diabetes.

Angiotensin converting enzymes (ACE) inhibitors, the most commonly prescribed form of antihypertensive medication, exert their action by stimulating the angiotensin II enzyme. Enzymes in the body convert angiotensin I to angiotensin II, a substance that slows the flow of blood through the coronary arteries and tightens the blood vessels. When this occurs, blood pressure is lowered and there is an improvement in the patient's clinical status. Angiotensin converting enzymes (ACE) inhibitors have been associated with a number of adverse side effects, however, most of these occurrences are related to their use in patients with severe hypertension. These side effects include weakness, vomiting, increased fluid retention, headache, and diarrhea.

Angiotensin II is a protein found in the kidneys and gastrointestinal tract. It is responsible for transporting calcium and other minerals into the bloodstream and away from the body. Studies indicate that there is a close relationship between blood pressure and the level of circulating Angiotensin II in patients with renal disease or those with elevated blood pressure. Patients who have undergone recent surgeries involving the kidney may experience an increase in blood levels of Angiotensin II. While using ace inhibitors to treat hypertension can be very effective, patients must be monitored regularly to ensure that the drug is not preventing the body from making enough of the vitamin. This can result in decreased blood pressure that still has high levels of normal serum calcium. In June 2020, Baudax Bio, Inc. launched ANJESO injection with ACE inhibitors.